New Abstral® partner in the US


Uppsala, Sweden – November 20, 2015 – Orexo AB (publ) today announced that the
US Abstral partner, Galena Biopharma Inc., has divested its Abstral business to
the privately held company Sentynl Therapeutics Inc. as a consequence of
Galena’s change of strategy to focus on its clinical development programs. The
divestment is effective as of November 19, 2015 and Orexo terms are unchanged
and passed on from Galena to Sentynl.

“We are pleased to see the interest in Abstral that has been revealed during
Galena’s divestment process and pleased to have a new and dedicated partner in
Sentynl. We are confident that Sentynl will manage to continue to grow the
Abstral business in the US,” said Nikolaj Sørensen, CEO and President of Orexo
AB.

For further information, please contact:
Nikolaj Sørensen, President and CEO, Orexo AB
Tel: +46 703 50 78 88, E-mail: ir@orexo.com

About Abstral®
Abstral is the leading fast-acting fentanyl product in EU intended for treatment
of breakthrough pain in cancer patients. Abstral employs Orexo’s proprietary
sublingual delivery technology (under the tongue). After the product development
Abstral was out-licensed to Kyowa Hakko Kirin Co., Ltd. and the European
subsidiary ProStrakan Group plc, which still holds the rights in the Japan and
EU respectively, whereas Galena Biopharma Inc. held the rights for Abstral in
the US until the divesture to Sentynl Therapeutics Inc. as of November 19, 2015.

For information about Abstral, please visit www.abstral.com.

About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary
product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an
advanced formulation of buprenorphine and naloxone using Orexo’s unique
knowledge and expertise in sublingual drug delivery. R&D is focusing on
reformulation of known substances to new improved products that meet great unmet
medical needs by using its patented proprietary technologies. Orexo’s share is
listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs
on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in
Uppsala, Sweden.

For more information please visit www.orexo.com and www.zubsolv.

Attachments

11201228.pdf